Charles Schwab’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Charles Schwab’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-175,689	Closed	-$44.8K	–	3751
2023 Q1	$44.8K	Hold	175,689	–	–	﹤0.01%	3365
2022 Q4	$207K	Buy	175,689 +4,948	+3%	+$10.4K	﹤0.01%	3180
2022 Q3	$349K	Buy	170,741 +150,851	+758%	+$256K	﹤0.01%	3092
2022 Q2	$31K	Hold	19,890	–	–	﹤0.01%	3470
2022 Q1	$101K	Buy	+19,890	New	+$90.4K	﹤0.01%	3413

Charles Schwab's PEAR Position: Q2 2023 in Review

Charles Schwab sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 175,689 shares — an estimated $44.8K sold.

Charles Schwab first reported a position in PEAR in Q1 2022 and held it in 5 quarters. The position peaked at $349K in Q3 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Charles Schwab reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Charles Schwab sold 175,689 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $44.8K.
Charles Schwab first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 5 quarters.
Charles Schwab's Pear Therapeutics, Inc. Class A Common Stock position peaked at $349K in Q3 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.